Rexulti (Brexpiprazole) Patent Expiration, LOE Window & CMS Spending

Rexulti (Brexpiprazole) by Otsuka Pharmaceutical: FDA Orange Book core substance LOE 2029-06-23 (last listed 2033-04-12), 1 AB generics, $1.34B 2024 CMS Part D & Medicaid spend, and 12 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorOtsuka Pharmaceutical
FDA Application & PathwayN205422 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2029-06-23
Last Listed Patent or Exclusivity Date2033-04-12
Orange Book Patents (*PED Extensions)10 patents (5 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$1.34B
2024 Medicare Part D Spend$861.4M
2024 Medicaid Spend$481.0M
Reported Wholesale Price Change (CA SB 17)12 WAC filings (max 21.8% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Otsuka Pharmaceutical across sibling Meru public-data platforms.